Pancreatic Cancer - Drug Pipeline Insight, 2026 | 170+ Companies and 200+ Therapies Signal Licensing, Investment, and Immuno-Oncology Growth Opportunities
Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Pancreatic Cancer - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.
This report provides a comprehensive analysis of the pancreatic cancer pipeline, covering more than 170 companies and 200 investigational therapies across clinical, preclinical and discovery stages. It evaluates pipeline products by development phase, product type, molecule type and route of administration while also examining discontinued and inactive candidates.
Pancreatic cancer remains one of the most aggressive malignancies and a leading cause of cancer-related mortality worldwide. Most cases are pancreatic ductal adenocarcinomas, with tumors frequently originating in the head of the pancreas. Reported 5-year survival rates generally range from 5% to 15%, reflecting late diagnosis, rapid disease progression and limited treatment options.
The disease is associated with metabolic abnormalities and resistance to growth-inhibitory pathways. Aberrant TGF? signalling can promote tumor growth, immune suppression and metastasis through effects within the tumor microenvironment. TGF? may also activate non-canonical signalling through mitogen-activated protein kinase phosphorylation, proto-oncogene tyrosine-protein kinase Src and AKT phosphorylation, while influencing WNT7B expression through SMAD4-dependent mechanisms.
Pancreatic cancer diagnosis typically combines contrast-enhanced CT, MRI, endoscopic ultrasound, laboratory testing and histopathological confirmation. CA 19-9 may support disease monitoring but is not considered reliable as a standalone diagnostic test. Treatment depends on disease stage. Surgical resection remains the principal curative option for localized tumors, often followed by chemotherapy or radiotherapy. Neoadjuvant therapy may improve resectability in borderline or locally advanced disease, while systemic chemotherapy and supportive care remain central to the management of unresectable or metastatic pancreatic cancer.
Pancreatic Cancer Pipeline Analysis
The report presents detailed clinical and commercial assessments of emerging pancreatic cancer therapies. Drug profiles include mechanisms of action, clinical study information, regulatory milestones, technology platforms, collaborations, licensing agreements, mergers and acquisitions, funding activities and product designations. The analysis also highlights unmet needs, recent research trends and novel technologies intended to address the limitations of existing pancreatic cancer treatments.
Pipeline candidates are assessed across Phase III, Phase II, Phase I, preclinical and discovery stages. The report also evaluates routes of administration, including intravenous, oral, parenteral, subcutaneous, topical and transdermal delivery, as well as molecule types such as oligonucleotides, peptides and small molecules. Products are categorized as monotherapies, combination therapies or candidates being investigated in both settings.
Selected Emerging Pancreatic Cancer Drugs
Competitive Landscape and Development Activity
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. is among the companies with a pancreatic cancer candidate in Phase III development. Other organizations active in the pipeline include Oncotelic Inc., Golden Biotechnology Corp., Cantargia AB, Marker Therapeutics, Inc., NanoPharmaceuticals, Innovent Biologics, Takeda, Verastem, Inc., Autotelic Bio Inc., Oncolytics Biotech, Agenus Inc., ONO PHARMACEUTICAL CO., LTD., Merck Sharp & Dohme LLC., Akeso Biopharma Co., Ltd., ImmunityBio, Inc., NETRIS Pharma, Can-Fite Biopharma and InxMed.
Additional pipeline products covered include IBI343, VS-7375, ATB-320, pelareorep, balstilimab, ONO-7913, lenvatinib, AK154, HCW9218, NP137, ifinatamab deruxtecan (MK-2400), patritumab deruxtecan (MK-1022), sacituzumab tirumotecan, NMK89, FG-M108, namodenoson and IN10018.
Key Report Insights
The report supports pharmaceutical companies, biotechnology organizations, investors and research institutions seeking to understand the evolving pancreatic cancer treatment landscape, identify development opportunities and assess the clinical and commercial potential of emerging drug candidates.
Key Topics Covered:
Introduction
Executive Summary
Pancreatic cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Pancreatic cancer- Analytical Perspective
Late Stage Products (Phase III)
TQB2868: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Mid Stage Products (Phase II)
Antroquinonol: Golden Biotechnology Corp.
Early Stage Products (Phase I)
MT-601: Marker Therapeutics, Inc.
Preclinical and Discovery Stage Products
fb-PMT: NanoPharmaceuticals
Inactive Products
Pancreatic cancer Key Companies
Pancreatic cancer Key Products
Pancreatic cancer - Unmet Needs
Pancreatic cancer - Market Drivers and Barriers
Pancreatic cancer - Future Perspectives and Conclusion
Pancreatic cancer Analyst Views
Appendix
List of Tables [12]
List of Figures [12]
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/xsm46d
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.